Teriparatide in the treatment of a loose hip prosthesis

Journal of Rheumatology

Volumn 38, Issue 4, 2011, Pages 778-7780

  Zati, Alessandro ^a   Sarti, Daniele ^b   Malaguti, Maria Cristina ^a   Pratelli, Loredana ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Ospedale SS Salvatore   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CLODRONIC ACID; PARATHYROID HORMONE[1-34];

AGED; BONE DENSITY; CASE REPORT; CORTICAL BONE; FEMUR; HIP DISEASE; HIP OSTEOARTHRITIS; HIP PAIN; HIP PROSTHESIS; HUMAN; JOINT STIFFNESS; LETTER; MALE; PRIORITY JOURNAL; PROSTHESIS LOOSENING; REOPERATION; WEIGHT BEARING;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; BONE AND BONES; BONE DENSITY; HIP PROSTHESIS; HUMANS; MALE; PROSTHESIS FAILURE; REOPERATION; TERIPARATIDE;

EID: 79953299174     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100980     Document Type: Letter

References (11)

1. Tsiridis E, Gamie Z, Conaghan PG, Giannodius PV. Biological options to enhance periprosthetic bone mass. Injury 2007;38:704-13. (Pubitemid 46726314)
2. Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, et al. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. Osteoporos Int 2008;19:373-7. (Pubitemid 351199179)
3. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40. (Pubitemid 19037656)
4. Miller PD, Shergy WJ, Body JJ, Chen P, Rohe, ME, Krege JH. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005;32:1556-62. (Pubitemid 41113979)
5. Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, et al. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 2006;17:1630-7. (Pubitemid 44477623)
6. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
7. Jiang Y, Zhao J, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41.
8. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-21. (Pubitemid 46049523)
9. Iolascon G, Gimigliano F, Resmini G. Teriparatide and orthopedic surgery. Aging Clin Exp Res 2007;19:22-5.
10. Brunnemann CE, Reisinger EC, Ganzer D, Schober HC. Parathyroid hormone injection to counteract delayed bone fractures. Dtsch Med Wochenschr 2010;135:1538-41.
11. Johansson HR, Skripitz R, Aspenberg P. Bisphosphonates can block the deterioration in implant fixation after withdrawal of intermittent doses of parathyroid hormone. J Bone Joint Surg Br 2008;90:400-4. (Pubitemid 351428963)